inflammation during movement, while allowing the initial inflammatory response to injury to proceed unimpaired. 
METHODS:
Full-thickness, excisional 1cm x 1cm wounds were created on the dorsum of C57BL/6 mice. Wounds were either left alone to heal as a control group, or were treated with PTP on the day the wounds were created. Wounds beds on animals in the treatment group received PTP treatment at a fluence of 60J/cm 2 . Wound areas were measured with serial photography for three weeks, at which time animals were euthanized and wound skin was harvested for histological processing with H&E and Masson's Trichrome staining. Histology was then reviewed by an expert dermatopathologist.
RESULTS:
PTP visually prevented wound contracture throughout the study. Wound size on serial photography was calculated as a percentage of the original wound area. Sizes of PTP-treated wounds were almost three times greater than controls after one week (68.6 ± 15% vs 25 ± 9%, p=0.004) and almost seven times greater after two weeks (38.8 ± 22% vs 5.6 ± 6%, p=0.05). At the end of the three-week study, while control wounds had visually completely closed, PTP-treated wounds were not yet closed and were over 10 times larger than control wounds (19.3 ± 20% vs 1.8 ± 2%, p=0.17). On histologic review, PTP treatment promoted increased ingrowth and development of dermal cells, increased vascularity, and development of skin appendages compared to control wounds.
CONCLUSION:
PTP prevents wound contracture in fullthickness, excisional wounds, and may accelerate the process of wound healing and development. These findings suggest future utility of PTP treatment not only for excisional wounds, but also for wounds with a high incidence of contracture and associated morbidity, including burns and skin-grafts.
PURPOSE:
Wound healing remains a global issue of disability, cost, and health. Addition of cells from the stromal vascular fraction of adipose tissue have been shown to increase the rate and quality of dermal wound healing. The present study aimed to investigate the angiogenic mechanisms of CD248+ stromal vascular fraction cells in the context of full thickness excisional wounds.
METHODS:
Single cell transcriptional analysis was used to identify angiogenic gene-expressing ASCs, then correlate with surface marker expression. SVF cells isolated from human lipoaspirate were FACS sorted based on the presence of CD248. Cells were analyzed for gene expression of VEGF and HGF, and subsequently assessed for tubule formation in vitro. Following this, 6mm full thickness dermal wounds were created on the dorsa of immunocompromised mice, supplied with a pullalan-collagen hydrogel, and separated into 4 treatment groups; CD248+, CD248-, unsorted SVF, and hydrogel alone. Wounds were measured every other day photometrically until closure. Once fully healed, wounds were harvested for histological analysis through CD31 immunohistochemical staining.
RESULTS:
Wounds treated with CD248+ cells healed significantly faster than the compared treatment groups. Moreover, immunohistochemistry of CD31 revealed a much higher presence of endothelial cells in the CD248+ group, indicating a large pro-angiogenic effect of CD248+ cells in vivo.
CONCLUSION: Therefore, using pro-angiogenic cells obtained from SVF presents a viable strategy in wound healing by proxy of increased vessel growth in the wound.
Human Mesenchymal Stromal Cells Engineered to Overexpress PDGF-B Using CRISPR/Cas9/rAAV6-based Tools Improve Wound Healing
Nina Kosaric, AB, Wai Srifa, BA, Geoffrey C. Gurtner, MD, Matthew H. Porteus, MD Stanford University, Stanford, CA PURPOSE: Mesenchymal Stromal Cells (MSCs) are a promising source for cell therapy due to their proregenerative and immunomodulatory effects. These properties can be enhanced by engineering MSCs to overexpress and secrete growth factors favorable to wound healing processes. Here, we aimed to develop a platform for targeted gene insertion in human bone marrow (hBM)-MSCs that utilizes CRISPR/Cas9 nuclease and recombinant adeno-associated virus serotype 6 (rAAV6) to deliver a designed homologous recombination-based repair template. Using this method, we engineered hBM-MSCs to overexpress and secrete soluble platelet derived growth factor B (PDGF-B) and examined the ability of this cell line to promote wound healing.
METHODS:
PDGF-B secreting hBM-MSCs (PDGFBhBM-MSCs) were generated by genome integration of a bicistronic PDGFB-2A-GFP expression cassette at the CCR5 locus. To examine the ability of these cells to promote wound healing, we utilized a diabetic murine excisional wound healing model. Wounds were treated with a single, local injection of PDGFB-hBM-MSCs, GFP-hBM-MSCs, or vehicle control (phosphate buffer saline (PBS)) immediately after wounding. The percentage change in wound size over time was used as a measure of the rate of wound healing.
RESULTS:
We observed accelerated wound healing kinetics in wounds treated with PDGFB-hBM-MSCs compared to wounds in the other treatment groups as early as day 13 after wounding, and this significant difference in healing rate persisted through 23 days postwounding. This resulted in significantly earlier wound closure in wounds treated with PDGFB-hBM-MSCs (20.2 days ± 0.68 days) compared with GFP-MSCs (25.4 days ± 0.83 days, p<0.0001) and PBS (26.33 days ± 0.67 days, p<0.0001). These data suggest that PDGF-B plays a critical role in the response to tissue injury during cutaneous wound healing, and that hBM-MSCs can be engineered to overexpress proteins to increase their therapeutic potential.
CONCLUSION:
Our engineering platform can be used to integrate a GFP reporter expression cassette into a genomic 'safe harbor' locus without changing the defining characteristics of MSCs. Using this platform, we successfully generated hBM-MSCs that overexpress and secrete PDGF-B, a growth factor essential to wound healing. Single, local injection of these cells under excisional wounds of diabetic mice at the time of wounding accelerates wound healing rates and reduces time to complete wound closure significantly when compared to injections of GFP-MSCs or a vehicle control.
